Published Date : Nov 2023
Category : Oncology
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

A Unique Perspective: Myeloma Market Insights Unleashed.

"Meeting the Challenge: Myeloma Market Assessment and Strategy."

A blood cancer called myeloma affects bone marrow cells, especially "plasma cells." A crucial component of the body's immune system are plasma cells. To assist the body fight diseases, they create antibodies. Multiple myeloma constitutes around 1% of all cancers globally and 10-15% of all haematological neoplasms.

When normal plasma cells undergo changes and uncontrolled cell growth, myeloma develops. As a result, there are more bone lesions, which raise the possibility of bone fractures. The annual chance of developing multiple myeloma is around 1%. However, the risk of advancement is about 10% each year in the first five years following diagnosis.

However, the cases of Myeloma are increasing worldwide. In 2020, the total number of cases for Myeloma was reported to be 176,404. However, the mortality for Myeloma in 2020 was reported to be 117,077. The treatment innovations and novel therapy research is required to reduce the burden of Myeloma from the world and improve the health of patient.

Myeloma cells make antibodies just like typical plasma cells do. However, myeloma cells are unable to create strong, useful antibodies. An alternative is "M protein," sometimes known as "monoclonal protein" or "monoclonal immunoglobulin." M protein accumulates in the blood and urine, raising the risk of kidney and other organ damage and lowering immunity.

However, A healthy individual is termed to have monoclonal gammopathy of unknown significance (MGUS) if a little quantity of this M protein is discovered in their body. There are 1% to 2% chances of person having monoclonal gammopathy to develop Myeloma, lymphoma, or other cancers.

The patients suffering Myeloma shows various signs and symptoms at various stage of the disease. The common symptom of Myeloma includes anaemia, fatigue, bone pain, numbness, weakness, hypercalcemia, weight loss, nausea, thirst, mental confusion, muscle weakness, blood clots, and fever and infections.

The below graph shows the most common symptoms of myeloma and their percentage contribution to the disease.

As shown in the above diagram, anemia is the most common symptom for myeloma which contributes 73%. After that bone pain measures for 58% and creatine elevation accounts for 48%. However, fatigue and hypercalcemia account for 32% and 28% respectively. In addition to that, weight loss contributes the lowest percentage which is 24%.

Moreover, according to NIH, only 1.8% of all new cancer cases diagnosed in the United States each year are multiple myeloma, making it a very uncommon disease. With a median age upon diagnosis of roughly 70 years, mostly affects the elderly population, and about only 2% of cases are of the below 40 age group.

However, myeloma affects men somewhat more frequently than women. NIH also states that compared to Whites, there appears to be a twofold rise in incidence in African American and black populations.

Furthermore, every year 6,500 new cases of myeloma are reported in Germany. In the United States, the estimated cases of Myeloma in 2023 are 35,730. However, out of the total cases, 19,860 are of men and 15,870 are of women. In addition to that, there were 12,590 deaths reported due to Myeloma in 2023 in which 7,000 men and 5,590 women died due to Myeloma.

Moreover, advancement in treatment therapy, novel medications, initiatives of governments for the prevention of Myeloma, and funding for research has increased the survival rate of the patient. In the United States, the 5-year survival rate for multiple myeloma is ~58%.

The market for myeloma is impacted by a variety of variables, such as its high prevalence and the absence of early diagnostic techniques. The sector is expanding due to several other variables, including the increasing prevalence of medical conditions worldwide and the difficulty in identifying the root causes of myeloma development.

These days, it is crucial to detect myeloma early. In the myeloma landscape, the development of curative medicines that are less expensive and have fewer side effects is also crucial. This provides several chances for market participants to enter this sector and gain new corporate value. 

DiseaseLandscape Insights here assists all industry players in choosing the best field for them to develop and build a strong business in the treatment as well as diagnostic field of Myeloma.

Diagnostic Analysis of Myeloma

"From Diagnosis to Innovations: Assessing the Myeloma Market."

The diagnosis of myeloma depends on the type of disease, signs, and symptoms of patients, age, physical health, and the medical history of the patient. The case history is the first step for diagnosis of myeloma which includes all the information about patients.

The following tests are used to diagnose the myeloma.

  1. Blood and Urine Test

Blood and urine tests are the basic steps and initial diagnostic tests for myeloma. Blood tests measure the level of M protein, immunoglobulin, serum albumin, lactate dehydrogenase, etc. Blood tests are also used to check for probable anemia and other low blood counts, as well as to check calcium levels, renal function, and blood cell counts.

  1. Imaging Tests

Imaging Tests provide detailed images of organs. Imaging tests help to determine the stage of myeloma. X-ray, computational tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) are the techniques available in the market for the diagnosis of myeloma.

  1. Bone Marrow Biopsy

Bone marrow biopsy is the removal of a small portion of solid skin from the patient and then analysis of it for certain biomarkers which confirms the diagnosis of myeloma. The biopsy does not show severe side effects but some common side effects are excessive bleeding, especially in those with low quantities of a certain type of blood cell (platelets). Infection, of the skin near the site of the exam, especially in persons with compromised immune systems.

Diagnostic tests are normally done in public laboratories provided with the required equipment and maintained by highly trained personnel. The market for myeloma diagnostics is highly crowded, with numerous industry players participating.

Industry businesses have the chance to discover breakthrough low-cost, accurate, and quick biopsy methods by using technology and substantial research. Diagnostic technique enhancements and development raise the bar for key stakeholders.

The below table shows the name of the industry player who is transforming the myeloma diagnostic domain with their advanced strategies are listed below.

                                                                         Diagnostic Market Player


Blood Test

Imaging Test


Cipla Ltd.

DiagnoTech Corporation

Innovia Medical

Sun Pharmaceuticals Industries Ltd.

UltraScan diagnostics

Becton, Dickinson, and Company

Thyrocare Technologies

Radiance Imaging System

Cardinal Health Inc.

Fortis Healthcare

Siemens Healthineers

Paramount Surgimed Limited

Apollo Diagnostics

Med Imaging Solutions

Integra LifeSciences


                                                                                 Diagnostic Products

Blood Tests

Imaging Tests


Flash CT Scanner

StatStrip Xpress®2

CX CT Scanner

EMS Stat ™


Isoton III®



Row CT Scanner

HMX Pak®

PreXion 3D Excelsior CBCT Scanner


Treatment Analysis for Myeloma

"Innovative Solutions: Establishing Myeloma Treatment Approaches."

Myeloma, a complicated and resistant type of cancer, poses an enormous challenge to patients and healthcare providers. Myeloma, a hematologic malignancy, has a significant influence on a person's life, impacting not only their physical health but also their mental well-being. In recent years, significant progress has been achieved in understanding and treating this condition.

Below are the therapies available in the market to treat the myeloma disease.

  1. Chemotherapy

Chemotherapy is the use of medications that destroy cancer cells, often by preventing cancer cells from growing, dividing, and proliferating. Chemotherapy side effects vary according to the individual and the quantity used, but they include exhaustion, infection risk, nausea and vomiting, hair loss, lack of appetite, and diarrhea or constipation. Peripheral neuropathy, blood coagulation issues, and low blood counts are among the other negative effects.

  1. Targeted Therapy

Targeted therapy is a type of cancer treatment that targets specific genes, proteins, or the tissue environment that contributes to cancer development and survival. This type of treatment prevents the proliferation and spread of cancer cells while safeguarding healthy cells.

Protease inhibitors, monoclonal antibodies, nuclear export inhibitors, B-cell maturation antigen targeting agents, and biospecific T-cell engagers are some of the targeted therapies used to treat myeloma.

In recent years, targeted therapy, also known as innovative therapy, has shown to be increasingly effective at managing myeloma and improving prognosis. In clinical trials, researchers continue to look at novel and changing medicines for this condition.

  1. Immunomodulatory Drugs

Immunomodulatory medications, such as Pomalidomide (Pomalyst) and Lenalidomide (Revlimid), trigger the immune system. Additionally, these medications prevent the growth of new blood vessels, which feed myeloma cells. Patients with recently diagnosed conditions use Thalidomide and Lenalidomide. Recurrent myeloma also be effectively treated with Pomalidomide and Lenalidomide.

  1. Bone Modifying Drugs

Bone-modifying medications are used to treat the majority of myeloma patients. These medications minimize bone pain and fracture risk while strengthening the bone. There are two classes of bone-modifying drugs available for managing the myeloma. One of which includes bisphosphonates and the other one is Denosumab (Xgeva).

Anemia, joint and muscle discomfort, flu-like symptoms, and renal issues are just a few of the potential side effects of bisphosphonates. Denosumab side effects might include nausea, anemia, back discomfort, and diarrhea.

  1. Immunotherapy

Immunotherapy enhances your immune system's capacity to target cancer cells to defeat the disease. The cellular immunotherapies idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti) are licensed to treat multiple myeloma.

However, these treatments use CAR (chimeric antigen receptor) T cells to attack BCMA. Myeloma cells have a protein called BCMA on their surface. When four or more treatments have failed to halt multiple myeloma, these therapies are utilized.

There are several potential for businesses in the myeloma therapy sector. Participants in the market concentrate on the creation of varied cost-effective therapeutic items, as well as the redevelopment of existing pharmaceuticals via the use of new technologies to improve patient health while improving the company's profit.

To keep stakeholders one step ahead in the market, DiseaseLandscape Insights undertakes significant research on the treatment area of myeloma disease. DLI services provide information about treatment choices, new medications and procedures, goods, and service offerings. DLI also conducts thorough research on rivals in the treatment sector and develops novel treatment solutions for better patient health.

The worldwide myeloma therapy market is very profitable, with a major market leader with a global presence. The table below illustrates the market players who are altering the myeloma disease area and pushing innovations to enhance healthcare outcomes, as well as their product names which are improving the health of patients.


Treatment Market Player



Denosumab (Xgeva)


Zoledronic acid (Zometa)

Biozenta Lifescience

Pamidronate (Aredia)

Mylan Pharmaceuticals Inc.

Lenalidomide (Revlimid)

Bristol Myers Squibb Pharmaceutical Corporation

Pomalidomide (Pomalyst)


Elranatamab (Elrexfio)

Janssen Biotech, Inc.

Talquetamab (Talvey)

Johnson & Johnson

Teclistamab-cqyv (Tecvayli)

GSK plc

Belantamab mafodotin-blmf (Blenrep)

Karyopharm Therapeutics Inc.

Selinexor (Xpovio)

Bristol Myers Squibb

Elotuzumab (Empliciti)


Daratumumab (Darzalex)

Takeda Pharmaceuticals

Bortezomib (Velcade)

Onyx Pharmaceuticals, Inc.

Carfilzomib (Kyprolis)

Takeda Pharmaceuticals

Ixazomib (Ninlaro)

Takeda Pharmaceuticals

Bortezomib (Velcade)

GlaxoSmithKline Group of Companies

Melphalan (Evomela)

Bristol-Myers Squibb

Carmustine (BiCNU)

Teva Pharmaceuticals

Bendamustine (Bendeka)


Regulatory Framework For Myeloma

"Compliant, Confident, Competent: Understanding the Regulatory Landscape."

DiseaseLandscape Insights summarizes regulatory requirements for myeloma from various nations. DLI offers empirical information on risk assessment, monitoring, and regulation compliance. Organizations and market participants avoid, manage, and respond to myeloma flare-ups while also preserving the safety of patients by researching the DiseaseLandscape Insights services.

However, Talquetamab-tgvs received accelerated approval from the Food and Drug Administration on August 9, 2023, for adults with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drugs, and an anti-CD38 monoclonal antibody.

In addition to that, Selinexor, in combination with bortezomib and dexamethasone, was authorized by the Food and Drug Administration on December 18, 2020, for the treatment of adult patients with multiple myeloma who have undergone at least one previous therapy.

Competitive Analysis

"Market Mastery: Harnessing Competitive Assessment."

Competitive analysis is an important part of strategy planning for healthcare corporations. DLI helps in assessing and comprehending the strengths and weaknesses of opponents in the healthcare business to make educated decisions and obtain a competitive advantage. Companies that invest in thorough competition analysis are better positioned to respond to industry changes and successfully address the demands of their patients and consumers.

However, K36 Therapeutics, Inc. is researching on small molecule inhibitor of the histone lysine methyl transferase MMSET to treat patients suffering from multiple myeloma by preventing the dimethylation of H3K36. Innovations and developments in such fields make the public aware of the disease and the product. The market for this product is demanding and that is why the revenue of the company also increases.

Moreover, companies like Fate Therapeutics are working on the drug FT576 as a monotherapy in combination with the monoclonal antibody daratumumab to treat myeloma. Such inventions and research help the patient to recover faster. The collaborations of Fate Therapeutics increase and the economy of the company is also boosted.

Market Trend

"Leading the Pack: Responding to Market Trends for Successful Business Establishment."

With the rising prevalence of myeloma and the development of new medicines, healthcare providers, researchers, and investors must remain up to date on the changing landscape of myeloma therapy. DLI looks into the most recent market trends and examines the exciting discoveries in therapeutics, the influence of precision medicine, the growing relevance of minimal residual disease monitoring, and the access and cost problems.

Significant progress has been made in the treatment of myeloma, including the introduction of new medications such as proteasome inhibitors (e.g., bortezomib), immunomodulatory therapies (e.g., lenalidomide), and monoclonal antibodies (e.g., daratumumab). These treatments have improved patient outcomes and increased patient survival rates. The opportunities in new drug development are grasping the attention of every key player in the market.

Also, immunotherapies, including CAR-T cell treatments, are being studied for their potential use in the treatment of multiple myeloma. These treatments use the ability of the immune system to recognize and eliminate cancer cells. Innovations and discoveries in such sectors are also trending nowadays. Stakeholders have tremendous scope in this domain to set up a business and generate huge revenue.

Moreover, research on combination medicine with different mechanisms of action to delay the progression of myeloma and improve the health of patients is another area where many industry players are focusing. Market participants should enter in this field to launch novel combination medicine to grow in this sector and build an economy.

Clinical Data Assessment

The increased government emphasis on comparative effectiveness studies emphasizes the importance of clinical trials in the field of evidence-based medicine and health care reform. One of the primary aims of healthcare reformation is achieved when market participants faithfully compare medical therapy using clinical data.

The table below lists the study names as well as the stages of the current clinical studies.

Phase I

Phase II

Phase III

Phase IV

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma

A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

A Multi-center, Open-label, Single-arm Clinical Study of Ixazomib/Pomalidomide/Dexamethasone (IxaPD) in the Treatment of Patients with Relapsed Multiple Myeloma

A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Phase 2 Study of Descartes-08 Consolidation Treatment in Patients with High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

A Single-center Clinical Trial to Evaluate the Efficacy and Safety of Colchicine Combined with Conventional Therapy in Multiple Myeloma Patients

Exploratory Study of Ixazomib in Combination with Reduced Dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High-Risk Multiple Myeloma

Phase 1 Trial of 111Indium/225Actinium-DOTA-Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed Refractory Multiple Myeloma

Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma

Study of Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following High-dose Melphalan Conditioning in Patients with Multiple Myeloma

Phase 1/2 Trial of Iberdomide in Combination with Daratumumab, BortEzomib, and DexamethAsone in Patients with Newly Diagnosed Multiple Myeloma (IDEAL)

Minimal Residual Disease Guided Maintenance Therapy with Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance

A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination with Lenalidomide for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma

A Phase 1 Study Evaluating the Safety of Venetoclax and Tocilizumab in African American and Non-African American Subjects with Relapsed or Refractory t (11;14) Multiple Myeloma

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination with Lenalidomide for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma

A Phase 1b/2 Study of Standard Doses of Bortezomib and Pembrolizumab ± Reovirus (Pelareorep) Combination Therapy in Patients with Relapsed Multiple Myeloma (AMBUSH Study)

A Phase II Trial of Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Combination with Selinexor for Patients with Newly Diagnosed Multiple Myeloma

A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination with Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients with High-risk Smoldering Multiple Myeloma

Clinical Study on the Effectiveness and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells for Lymphoma and Multiple Myeloma



Disease Landscape Insights (DLI) research and consulting services offer facts that guide strategic choices and promote innovation, making it an invaluable resource for business professionals, regulators, investors, and healthcare providers. Players need to work together, adapt, and grab chances for development and improvement as the myeloma market continues to change.

DLI services provide the knowledge and perspective required by the major parties associated with the manufacture of therapeutic products. With the guidance of DiseaseLandscape Insights, organizations operating in the market more easily plan and carry out clinical trials for novel therapies and pharmaceuticals, patient recruitment strategies, and regulatory compliance.

These opportunities allow researchers to conduct specialized R&D, learn about contract manufacturing sectors, and discover the vendors of raw materials. All market participants receive assistance from DiseaseLandscape Insights (DLI) in gaining better momentum in the myeloma sector.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape